Many researchers believe that GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes, depression and bipolar disorder, and some forms of cancer. This book provides a thorough introduction to GSK-3, presents up-to-date information, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity. It's a great reference for researchers in drug design and development.

Since the pioneering pharmacotherapy for treatment of schizophrenia in the 1950s by antipsychotics, only a few major innovations have been made, pointing to a general stagnation in the field of pharmacology of schizophrenia. Drug Discovery for Schizophrenia covers new insights in the field of schizophrenia with an aim to advance the understanding of scientists and clinicians in this area and to fuel drug discovery. The book outlines a change in the way schizophrenia is treated by moving away from focusing only on treating symptoms in patients. Innovative drugs emerge from...

This book addresses the various classes of privileged scaffolds and covers the history of their discovery and use.